InfuSystem (INFU) Stock Price, News & Analysis

Company Overview

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Key Stats

• Today's Range: $4.67 to $5.21
• 50-Day Range: $4.80 to $8.79
• 52-Week Range: $4.61 to $9.97
• Volume: 232,888 shs
• Average Volume: 80,427 shs
• Market Capitalization: $106.55 million
• P/E Ratio: 84.51
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Strong Buy

InfuSystem Stock Analysis - MarketRank™

InfuSystem scored higher than 28% of companies evaluated by MarketBeat, and ranked 800th out of 904 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

InfuSystem has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 106.67%

Earnings Growth

Earnings for InfuSystem are expected to grow by 106.67% in the coming year, from $0.15 to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InfuSystem is 84.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.18.

Price to Earnings Ratio vs. Sector

The P/E ratio of InfuSystem is 84.51, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.21.

Price to Book Value per Share Ratio

InfuSystem has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for INFU.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InfuSystem does not currently pay a dividend.

Dividend Growth

InfuSystem does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for INFU.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for INFU on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added InfuSystem to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InfuSystem insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.20% of the stock of InfuSystem is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.13% of the stock of InfuSystem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INFU Stock Analysis - Frequently Asked Questions

How have INFU shares performed this year?

InfuSystem's stock was trading at $8.45 at the beginning of the year. Since then, INFU stock has decreased by 40.0% and is now trading at $5.07.
View the best growth stocks for 2025 here.

How were InfuSystem's earnings last quarter?

InfuSystem Holdings, Inc. (NYSE:INFU) posted its quarterly earnings results on Thursday, November, 7th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. The company had revenue of $35.32 million for the quarter, compared to analyst estimates of $35.50 million. InfuSystem had a net margin of 1.12% and a trailing twelve-month return on equity of 2.78%.

Who are InfuSystem's major shareholders?

Top institutional investors of InfuSystem include Kings Path Partners LLC (0.16%). Insiders that own company stock include Richard Dilorio, Christopher R Sansone, Carrie Lachance, Barry G Steele, Paul Andrew Gendron, R Rimmy Malhotra, Thomas Mark Ruiz, Addam Chupa, Ralph F Boyd Jr, Kevin Whitman, Kenneth D Eichenbaum and Gregg Owen Lehman.
View institutional ownership trends.

How do I buy shares of InfuSystem?

Shares of INFU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InfuSystem own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InfuSystem investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 4/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:INFU
• Previous Symbol: NYSE:INFU
• CIK: 1337013
• Web: www.infusystem.com
• Phone: (248) 291-1210
• Fax: 800-455-4338
• Employees: 410
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $13.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +156.4%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 4.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.10
• Trailing P/E Ratio: 84.51
• Forward P/E Ratio: 33.80
• P/E Growth: N/A
• Net Income: $870,000.00
• Net Margins: 1.12%
• Pretax Margin: 2.65%
• Return on Equity: 2.78%
• Return on Assets: 1.41%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.98
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $134.86 million
• Price / Sales: 0.79
• Cash Flow: $0.40 per share
• Price / Cash Flow: 12.79
• Book Value: $2.47 per share
• Price / Book: 2.05

Miscellaneous

• Outstanding Shares: 21,016,000
• Free Float: 19,095,000
• Market Cap: $106.55 million
• Optionable: Optionable
• Beta: 1.90